Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sage trade maybe you should join wriggly over at CHF
I think if your a short term trader this RNS is not what you wanted but if your an investor/patient all is good just taking a touch longer than anticipated
Thanks for your kind words and sorry for offering my
opinion on, yes - an opinion board.
What a piece of work you are...
Yes Ferdinand, next year it is I guess..
Sagetrade
It does depend on your bias to the announcement. I think there are possibilities to be optimistic or pessimistic that progress will be slower than expected. I am optimistic as I am a long term holder. If you are in for short term profits you might not get the 4 pounds price target so many have been seeking in the short term.
I hope you don't get abuse but suspect you might...unfortunately.
Everyone is reading... it is a LONG one
We have several momentous milestones ahead of us .....
Looks unlikely to launch before 2021 based on the below, so wont be used to resolve the current testing problems. I’m also amazed they haven’t thought about the scale up of manufacturing before now...
“Avacta's product development strategy is to initially self-certify the lateral flow test for professional use, which it will be in a position to do as soon as the verification and clinical validation data is gathered. In order for the product to be CE marked for consumer self-testing a "lay user study" must be carried out, which evaluates the usability of the test by lay persons to ensure that the test can be carried out successfully and safely by the consumer. This study will be carried out as soon as is practically possible and in parallel with other activities. The completed technical file covering verification, validation and the lay user study will then be submitted to Avacta's notified body for auditing and certification before direct-to-consumer product sales can commence.
Cytiva is now working with BBI Solutions to establish a scalable manufacturing process. This process involves developing methods which are different from those used in the laboratory to develop prototypes, which must work at scale to deliver a mass-produced test strip with the required performance. When this scale-up process is completed and the first pilot batch of lateral flow test devices is produced, a critical technical hurdle will have been overcome. Avacta's intention is to use the pilot batch devices for clinical validation in Q4 using patient samples. When the first pilot batch is completed successfully, it will become possible to define the timeline to clinical validation and CE marking of both the professional and consumer use products with a greater degree of certainty and the Group will then communicate that timeline to product launch to the market. In the meantime Avacta continues to support its partners in reaching pilot batch production.”
They are stuck in this phase for many months now but still no explanation given. Hopefully presentation will be clearer. And its not NDA as all so called experts here been saying.
“When the first pilot batch is completed successfully, it will become possible to define the timeline to clinical validation and CE marking of both the professional and consumer use products with a greater degree of certainty and the Group will then communicate that timeline to product launch to the market. In the meantime Avacta continues to support its partners in reaching pilot batch production.”
Wow - where is everyone
Does it? Suppose it does if you take the CEO’s rhetoric as gospel.
Devil in the detail:
- BAMS delay due to lack of samples within condor - no manufacturing partners in place yet
- LFT miles away (early 2021 for sales) IMO. Tech transfer still not complete, separate study needed for direct to consumer use (ie Moonshot), doesn’t explicitly say we are in CONDOR for LFT whereas it does for BAMS. Also an admission of how difficult it is to set up mass production vs prototype build.
Risk, reward scales moving in the wrong direction IMO...cue the abuse !
It will be a very exciting and genuinely transformational year ahead for Avacta, as we work with our partners to progress through each of the necessary stages to deliver on all of these opportunities and I look forward to keeping the market updated as we hit the major milestones."
Says it all really